This year, the Cancer Research Society (the Society) will award 80 research grants valued at $9.6 million dollars; a new record for the organization! These grants are awarded to some of the most promising cancer research projects in Canada.

The Society receives hundreds of applications annually from researchers and clinicians in Canada, all seeking to obtain a $120,000 two-year grant for a cancer research project. Additionally, the Society awards special grants for the next generation of scientists, with the aim of supporting researchers who are at the start of their careers. This year, 4 researchers will receive this special grant. The Society is the only Canadian institution that has been offering such a grant and it has been doing so since 2013.

“As a leader in the field of cancer research in Canada, the Cancer Research Society is determined, now more than ever, to contribute to preventing, detecting and treating all types of cancer as demonstrated by the success of our annual grant competition. Each donor and partner can be sure that the donations collected will have a major impact for patients diagnosed with cancer, as well as for their loved ones.”
– Manon Pepin, President and Chief Executive Officer of the Cancer Research Society

Discover some of the researchers' profiles and their innovative proposals by clicking here.

The financial support offered by the Society is made possible thanks to the generosity of thousands of donors and partners that co-finance particular grants such as Ovarian Cancer Canada, the Quebec Breast Cancer Foundation, the CURE Foundation, Canadian Institutes of Health Research - Institute of Cancer Research (CIHR-ICR), Canadian Institutes of Health Research - Institute of Musculoskeletal Health and Arthritis (IMHA) and The Leukemia and Lymphoma Society of Canada, as well as one of the grants funded by the Bank of Montreal.

The research projects were chosen using a rigorous process; committees composed of over 95 researchers and clinicians generously gave of their time to select the most promising projects from among the 350 applications received.

“The Society thanks all the experts who conducted the exhaustive analysis of the projects and congratulates researchers and clinicians who were awarded a grant or bursary. They all have the potential of making remarkable progress to outsmart cancer.”
– Dajan O’Donnell, Director, Scientific Affairs and Partnerships, Cancer Research Society

Recall that the Society continues to finance grants and bursaries that began in previous years, in addition to particular special partnership research projects.

Here is the list of all the researchers selected.

Causes and prevention - the most effective approach to reducing the risk of developing the disease

Laura Anderson

McMaster University – funded in partnership with the Canadian Institutes of Health Research - Institute of Cancer Research

Identifying changes in cancer risk factors during the COVID-19 pandemic and predicting population risk

Parveen Bhatti

BC Cancer

Metabolomic markers to target prevention of postmenopausal breast cancer among overweight and obese women

Roberto Botelho

Ryerson University

The importance of phosphoinositide acyl regulation in cancer cell biology

Colin Collins

University of British Columbia

Identification and functional validation of genes driving therapy-induced dormancy in prostate cancer

Jean-François Côté

Montreal Clinical Research Institute – funded in partnership with The Quebec Breast Cancer Foundation

A deadly kinase promotes triple-negative breast cancer progression: defining the functions of PEAK1 protein complexes in tumour growth and metastasis

Michael Cox

University of British Columbia

How prostate cancer subtypes impact bone microarchitecture in metastatic lesions

Juliet Daniel

McMaster University

Kaiso, intestinal inflammation and colon cancer

John Di Guglielmo

University of Western Ontario

Targeting the type II TGFß receptor as a novel strategy for lung cancer

Savraj Grewal

University of Calgary

Oncogenic Ras signalling, and the metabolic regulation of hematopoietic tumours and whole-body physiology

David Hipfner

Montreal Clinical Research Institute

A Drosophila model of cell-cell growth signalling through filopodia

Pamela Hoodless

BC Cancer – funded in partnership with the Environment-Cancer FundTM of the Cancer Research Society and Read for the Cure

Defining epigenetic alterations in liver cancer at single cell resolution

Nina Jones

University of Guelph – funded in partnership with the Canadian Institutes of Health Research - Institute of Cancer Research

Investigating the role of ShcD signalling in metastatic breast cancer

Mathieu Laplante

Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval

Defining the role of ZNF768 overexpression in lung cancer development

Mohan Malleshaiah

Montreal Clinical Research Institute – funded in partnership with the Canadian Institutes of Health Research - Institute of Cancer Research

Single-cell analysis of the epithelial-to-mesenchymal transition in pancreatic cancer

Nathalie Rivard

Université de Sherbrooke

Exploring the role of Shp-2 in APC-mutated colorectal cancer

Rola Saleeb

St. Michael's Hospital – funded in partnership with the Canadian Institutes of Health Research - Institute of Cancer Research

Tracing the origin of kidney cancer from renal stem cells, understanding tumour pathogenesis for effective cancer prevention

Vivian Saridakis

York University

Identifying substrates of a critical E3 ligase in prostate cancer

Thomas Simmen

University of Alberta – funded in partnership with the Canadian Institutes of Health Research - Institute of Cancer Research

Rab32 promotes autophagic elimination of a metabolism control centre in breast cancer

Ulrich Tepass

University of Toronto

Mitosis as a driver of epithelial tumour progression

Hugo Wurtele

Centre de recherche de l’Hôpital Maisonneuve-Rosemont

Nascent chromatin structure as a modulator of cellular senescence in cancer

Detection – early detection is critical to improving patient outcomes

Scott Bratman

University Health Network (Princess Margaret Cancer Centre)

Methylated DNA as a novel early detection test for oral squamous cell carcinoma

Pejman Jabehdar Maralani

Sunnybrook Research Institute

Advanced MRI for non-invasive mapping glioma stem cells in glioblastoma

Thanh Nguyen

The Ottawa Hospital

Magnetic resonance spectroscopy as a non-invasive tool to diagnose and monitor gliomas

Neil Renwick

Queen's University – funded in partnership with the Steven E and Scott Drabin Research Fund

Evaluating microRNAs as tissue and circulating biomarkers for gastroenteropancreatic neuroendocrine neoplasms

John Trant

University of Windsor

Early identification of neuroendocrine-like prostate cancer using near-infrared light

Maruti Uppalapati

University of Saskatchewan – funded in partnership with the Canadian Institutes of Health Research - Institute of Cancer Research

Development of molecular imaging probes targeting Nectin4 (PVRL4) expression in cancer

Treatment – the development of new treatments, including targeted or personalized therapies

Tommy Alain

CHEO Research Institute – funded in partnership with the Canadian Institutes of Health Research - Institute of Cancer Research

Oral administration of Reoviruses for the treatment, prevention and early diagnosis of colorectal cancer

Vincent Archambault

Université de Montréal

Enhancing immunogenic nuclear assembly defects after cell division

Steve Bilodeau

Université Laval

Targeting the HSF1-regulated pathway in endocrine-resistant breast cancer to restore antiestrogen response

Peter Black

University of British Columbia

Assessment of IL-10 driven N-glycan branching as a regulator of CD8 T cell function in muscle-invasive bladder cancer

Jeanette Boudreau

Dalhousie University – funded in partnership with the Canadian Institutes of Health Research - Institute of Cancer Research

Immune evasion from natural killer cells by non-small cell lung cancer

Marie-Claude Bourgeois-Daigneault

Centre de recherche du CHUM – funded in partnership with the Canadian Institutes of Health Research - Institute of Cancer Research

Investigating the role of the immunoproteasome in the efficacy of oncolytic virotherapy against breast cancer

Byram Bridle

University of Guelph

Heat and cold adaptation of oncolytic rhabdoviruses to improve their clinical utility

John Burke

University of Victoria

Defining the molecular mechanism of activation of oncogenes in the PIP3/PDK1/Akt signalling pathway

Steven Chan

University Health Network (Princess Margaret Cancer Centre) – funded in partnership with The Leukemia & Lymphoma Society of Canada

Targeting SYK signalling to overcome resistance to IDH inhibitors in acute myeloid leukemia

Audrey Claing

Université de Montréal – funded in partnership with the Canadian Institutes of Health Research - Institute of Cancer Research

Role of ARF1 as a key GTPAse regulating immune surveillance in breast cancer

Marc Coppolino

University of Guelph – funded in partnership with the Canadian Institutes of Health Research - Institute of Cancer Research

Preventing breast cancer metastasis by disrupting MT1-MMP trafficking

Shoukat Dedhar

BC Cancer – funded in partnership with the Canadian Institutes of Health Research - Institute of Cancer Research

The role of microbiota and immune microenvironment in breast cancer metastasis

Javier Di Noia

Montreal Clinical Research Institute – funded in partnership with The Leukemia & Lymphoma Society of Canada

An orphan deaminase as a novel source of chemotherapy resistance in cancer

Jean-Simom Diallo

Ottawa Hospital Research Institute

Discovery of novel liposarcoma antigens for immunotherapy development

Phedias Diamandis

University Health Network (Princess Margaret Cancer Centre) – funded in partnership with the Canadian Institutes of Health Research - Institute of Cancer Research

Exploring the role and therapeutic potential of hypoxia-driven AKAP12 expression in glioblastoma

Pierre-Olivier Fiset

Research Institute of the McGill University Health Centre – funded in partnership with the Canadian Institutes of Health Research - Institute of Cancer Research

Unlocking new options for patients with squamous cell carcinoma of the lung

Suresh Gadde

University of Ottawa – funded in partnership with The CURE Foundation

RNAi-chemotherapy combination nanomedicines for the effective treatment of triple-negative breast cancer

Etienne Gagnon

Institute for Research in Immunology and Cancer of the Université de Montréal – funded in partnership with The Leukemia & Lymphoma Society of Canada

Optimizing and benchmarking novel modular CARs targeting leukemia.

Armin Gamper

University of Alberta

Improving cervical cancer therapy with radiosensitizers for brachytherapy

Jean-Philippe Gratton

Université de Montréal

Role of PAK2 in tumour angiogenesis and in the tumour microenvironment

Simon-Pierre Gravel

Université de Montréal

The PGC-1 metabolic coactivators control immunosuppression and response to immunotherapy in melanoma

Martin Guimond

Centre de recherche de l’Hôpital Maisonneuve-Rosemont – funded in partnership with The Leukemia & Lymphoma Society of Canada

The effect of EGFL7 on graft-versus-host disease and graft-versus-leukemia effect

Patrick Gunning

University of Toronto – funded in partnership with The Leukemia & Lymphoma Society of Canada

Development of selective HDAC inhibitors for the treatment of hematological malignancies

Xi Huang

SickKids

Tissue stiffness heterogeneity is governing the replicative potential and chemosensitivity of brain tumour-initiating cells

Carolina Ilkow

Ottawa Hospital Research Institute – funded in partnership with the Canadian Institutes of Health Research - Institute of Cancer Research

Understanding the role of adipose tissue and fat cells in cancer virotherapy resistance

Valentin Jaumouillé

Simon Fraser University – funded in partnership with The Leukemia & Lymphoma Society of Canada

Understanding and exploiting the mechanobiology of macrophages to promote clearance of lymphoma cells by phagocytosis

Éric Lévesque

CHU de Québec - Université Laval

Aberrant UGT2B28 androgen inactivation pathway predicts prostate cancer progression

William Lockwood

BC Cancer

Managing EGFR inhibitor resistance in lung adenocarcinoma through drug holiday- induced hyperactivation of oncogenic pathways

Rachid Mazroui

Université Laval

Role of DDX3-ALKBH5 interaction in ATF4 mRNA translation: implications in chemoresistance

Judith Andrea McCart

Mount Sinai Hospital

Investigating the role of innate immune responses in the anti-tumor effects of oncolytic vaccinia virus

Jane McGlade

SickKids – funded in partnership with The Leukemia & Lymphoma Society of Canada

GADS dependent signalling networks in BCR-ABL driven leukemia

Peter Metrakos

Research Institute of the McGill University Health Centre

Role of innate immune cells in the development of vessel co-option

Eric Milot

Centre de recherche de l’Hôpital Maisonneuve-Rosemont – funded in partnership with The Leukemia & Lymphoma Society of Canada

Influence of Ikaros on treatment response in acute lymphocytic leukemia

Christopher Mueller

Queen's University – funded in partnership with the Helen Lenore Bailey Fund

A Liquid Biopsy for Monitoring Treatment Response to Immunotherapy in NSCLC

Yvonne Myal

University of Manitoba – funded in partnership with the Canadian Institutes of Health Research - Institute of Cancer Research

The role of prolactin-inducible protein (PIP) in promoting breast cancer metastasis in the lung

Michael Olson

Ryerson University – funded in partnership with Ovarian Cancer Canada

MRCK in high-grade serous ovarian cancer: defining pathways promoting cell proliferation and mechanisms of drug resistance

Ayman Oweida

Université de Sherbrooke – funded in partnership with the Canadian Institutes of Health Research - Institute of Musculoskeletal Health and Arthritis

Targeting immunosuppressive chemokines for enhanced response to radiotherapy in squamous cell cancers

Morag Park

McGill University – funded in partnership with The Quebec Breast Cancer Foundation

B7-H4 as a therapeutic target in poor-outcome triple-negative breast cancers

Moutih Rafei

Université de Montréal – funded in partnership with The Leukemia & Lymphoma Society of Canada

Enhancing endosome-to-cytosol import of antigen to augment antitumoral immunity

Mir Munir Rahim

University of Windsor – funded in partnership with the Canadian Institutes of Health Research - Institute of Cancer Research

Immunosurveillance of breast cancer by innate immune cells

Gregor Reid

University of British Columbia

Prospective characterization of relapse-driving blasts in acute lymphoblastic leukemia

Francis Rodier

Centre de recherche du CHUM – funded in partnership with The Leukemia & Lymphoma Society of Canada

Evaluating new pharmacologically targetable molecular hallmarks of premature aging in childhood blood cancer survivors

Philippe Roux

Institute for Research in Immunology and Cancer of the Université de Montréal

Targeting CDK12 to overcome melanoma chemoresistance

Tanveer Sharif

University of Manitoba – funded in partnership with the Canadian Institutes of Health Research - Institute of Cancer Research

Therapeutic exploitation of metabolic rewiring in tumour heterogeneity

Trevor Shepherd

University of Western Ontario

Therapeutic targeting of ULK1, a crucial regulator of autophagic stress in metastatic ovarian cancer

Maya Shmulevitz

University of Alberta – funded in partnership with the Canadian Institutes of Health Research - Institute of Cancer Research

Overcoming inactivation of oncolytic reovirus by proteases in breast tumour microenvironments

Matthew Smith

Université de Montréal

Structure-function analysis of a novel KRAS effector complex and its role in metastasis

Sebastien Talbot

Université de Montréal – funded in partnership with the Canadian Institutes of Health Research - Institute of Cancer Research

Tumour-innervating PDL1-positive neurons block cancer immunosurveillance

Laura Trinkle-Mulcahy

University of Ottawa

Contribution of a novel nuclear stress response to pro-survival signalling and stress adaptation

Jim Uniacke

University of Guelph

Ribosomal protein S24 isoforms in adaptation to hypoxia and cancer progression

Barbara Vanderhyden

Ottawa Hospital Research Institute

Defining LATS1/2 as drivers of ovarian cancer and its immune suppressive microenvironment

Franco Vizeacoumar

University of Saskatchewan – funded in partnership with the Charlotte Légaré Memorial Fund

Developing novel targeted therapies for telomerase-overexpressing pancreatic cancers

Donna Wall

SickKids

Revisioning autologous transplant in pediatric solid tumors

Gelareh Zadeh

University Health Network (Princess Margaret Cancer Centre)

Uncovering the oncogenic potential of CIC-fusions and JAK/STAT1/3 activation in CIC‑rearranged sarcomas

Recipients of the Scholarship for the Next Generation of Scientists (SNGS)

Barbara Grünwald

University Health Network (Princess Margaret Cancer Centre) – funded in partnership with BMO Financial Group

Part 1 : Fibroblast populations determining regional microenvironmental states in pancreatic cancer
Part 2 : Divide and conquer: defining functional units in pancreatic cancer stroma

Joshua Moreau

University of California, San Francisco

Part 1 : Dissecting the functional role of layilin on tumour-infiltrating T cells
Part 2 : Untangling the duelling pro- and anti-cancer potential of tumour-infiltrating B cells

Dominic Roy

McGill University –Rosalind and Morris Goodman Cancer Institute

Part 1 : Metabolic regulation of oncolytic virotherapy
Part 2 : Targeting glycolysis to improve oncolytic virotherapy

Dheva Setiaputra

Lunenfeld-Tanenbaum Research Institute

Part 1 : Uncovering the molecular mechanisms of DNA double-strand break repair
Part 2 : Dissecting DNA double-strand break repair and its role in cancer biology